SEC Form 4 · accession 0001562180-17-002434
Akebia Therapeutics, Inc. · AKBA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Nicole R. Hadas
Officer — SVP, General Counsel, Sec.
Period of report
Jul 3, 2017
Accepted (ET)
Jul 6, 2017 · 12:24 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001517022
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3 | Jul 3, 2017 | S | 1,554 | $14.2577 | D | 109,607 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares sold by reporting person to pay taxes in connection with the vesting of restricted stock pursuant to a December 23, 2013 award. Twenty-five percent of the shares vested on December 2, 2014, and the remaining shares vest in equal quarterly installments through October 1, 2017.
- F2The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.11 to $14.41, inclusive. The reporting person undertakes to provide Issuer, any security holder of Issuer, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
- F3The total amount of beneficial securities includes 1,305 shares of stock purchased on June 30, 2017 at $8.92 per share in connection with the Issuer's Employee Stock Purchase Plan.